Pharmacogenetics of antidepressant response

References

• Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality, injuries, and risk factors in1990 and projected to 2020. In: Global Burden of Disease and Injury Series, Volume I. Harvard School of Public Health, MA, USA (1996).
   Google Scholar
• Doris A, Ebmeier K, Shajahan P. Depressive illness. Lancet354(9187), 1369–1375 (1999).
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Van GE, Gregoire J, Gaens E, Mesters P. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int. Clin. Psychopharmacol.13(1), 11–17 (1998).
   PubMed Web of Science ®Google Scholar
• Uher R, Farmer A, Henigsberg N et al. Adverse reactions to antidepressants. Br. J. Psychiatry195(3), 202–210 (2009).
   PubMed Web of Science ®Google Scholar
• Angst J. [Effect of antidepressives and genetic factors]. Arzneimittelforschung14(Suppl.), 500 (1964).
   Google Scholar
• Pare CM, Rees L, Sainsbury MJ. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet2(7270), 1340–1343 (1962).
   PubMed Web of Science ®Google Scholar
• O’Reilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol. Psychiatry36(7), 467–471 (1994).
   PubMed Web of Science ®Google Scholar
• Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J. Psychiatr. Res.32(5), 255–259 (1998).
   PubMed Web of Science ®Google Scholar
• Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol. Ther.41(3), 535–552 (1989).
   PubMed Web of Science ®Google Scholar
• Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther. Drug Monit.22(2), 202–208 (2000).
   PubMed Web of Science ®Google Scholar
• Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther.63(4), 444–452 (1998).
   PubMed Web of Science ®Google Scholar
• Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br. J. Clin. Pharmacol.41(2), 149–156 (1996).
   PubMed Web of Science ®Google Scholar
• Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur. J. Clin. Pharmacol.56(2), 175–180 (2000).
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Brosen K, Gram LF et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin. Pharmacol. Ther.51(3), 278–287 (1992).
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Tyndale RF, Reed K et al. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J. Clin. Psychopharmacol.19(5), 472–475 (1999).
   PubMed Web of Science ®Google Scholar
• de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J. DOI: 10.1038/tpj.2010.39 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther.83(2), 322–327 (2008).
   PubMed Web of Science ®Google Scholar
• Huezo-Diaz P, Perroud N, Spencer E et al. Effect of CYP2C19 genotype on steady-state escitalopram level in GENDEP. J. Psychopharmacol. (2010) (In press).
   Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther.116(3), 496–526 (2007).
   PubMed Web of Science ®Google Scholar
• Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin. Pharmacol. Ther.81(6), 899–902 (2007).
   PubMed Web of Science ®Google Scholar
• Steimer W, Zopf K, von Amelunxen S et al. Amitriptyline or not, that is the question: Pharmacogenetic testing of CYP2D6 and CYP219 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem.51(2), 376–385 (2005).
   PubMed Web of Science ®Google Scholar
• Lessard E, Yessine MA, Hamelin BA, O’Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics Genom.9(4), 435–443 (1999).
   Google Scholar
• Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry9(5), 442–473 (2004).
   PubMed Web of Science ®Google Scholar
• Pfuhlmann B, Gerlach M, Burger R et al. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J. Neural Transm. Suppl (72), 287–296 (2007).
   PubMedGoogle Scholar
• Ulrich S, Lauter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin. Pharmacokinet.41(11), 853–876 (2002).
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Brosen K. Is therapeutic drug monitoring for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther. Drug Monit.22(2), 143–154 (2000).
   PubMed Web of Science ®Google Scholar
• Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992–1997. Ther. Drug Monit.25(2), 183–191 (2003).
   PubMed Web of Science ®Google Scholar
• Grasmader K, Verwohlt PL, Rietschel M et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur. J. Clin. Pharmacol.60(5), 329–336 (2004).
   PubMed Web of Science ®Google Scholar
• Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am. J. Psychiatry160(10), 1830–1835 (2003).
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, Kraft JB et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One3(4), e1872 (2008).
   PubMed Web of Science ®Google Scholar
• Serretti A, Calati R, Massat I et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int. Clin. Psychopharmacol.24(5), 250–256 (2009).
   PubMed Web of Science ®Google Scholar
• Keers R, Uher R, Rietschel M et al.CYP2D6 and CYP2C19 genotype predicts antidepressant dose in the GENDEP project. Eur. Neuropsychopharmacol.20(Suppl. 1), S70 (2010).
   Google Scholar
• Keers R, Ingelman-Sundberg M, Hauser J et al.CYP2D6 genotype predicts antidepressant dose in the GENDEP project. Eur. Neuropsychopharmacol.20(Suppl. 3), S172 (2010).
   Google Scholar
• Ejsing TB, Linnet K. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood–brain barrier. Hum. Psychopharmacol.20(2), 149–153 (2005).
   PubMed Web of Science ®Google Scholar
• Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry54(8), 840–846 (2003).
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol.62(1), 1–6 (2002).
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7), 3473–3478 (2000).
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther.112(2), 457–473 (2006).
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Eap CB, Oneda B et al.CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther. Drug Monit.30(4), 474–482 (2008).
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Serretti A et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry32(2), 398–404 (2008).
   PubMed Web of Science ®Google Scholar
• Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol. Res.58(5–6), 344–347 (2008).
   PubMed Web of Science ®Google Scholar
• Mihaljevic PA, Bozina N, Sagud M, Rojnic KM, Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry32(6), 1439–1444 (2008).
   PubMed Web of Science ®Google Scholar
• Uhr M, Tontsch A, Namendorf C et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron57, 203–209 (2008).
   PubMed Web of Science ®Google Scholar
• Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM Jr. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet. Genomics20(8), 467–475 (2010).
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Zanardi R, Benedetti F, Di BD, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry3(6), 508–511 (1998).
   PubMed Web of Science ®Google Scholar
• Kim DK, Lim SW, Lee S et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport11(1), 215–219 (2000).
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology23(5), 587–590 (2000).
   PubMed Web of Science ®Google Scholar
• Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol.20(1) (2000).
   PubMedGoogle Scholar
• Zanardi R, Serretti A, Rossini D et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry50(5), 323–330 (2001).
   PubMed Web of Science ®Google Scholar
• Ito K, Yoshida K, Sato K et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res.111(2–3), 235–239 (2002).
   PubMed Web of Science ®Google Scholar
• Rausch JL, Johnson ME, Fei YJ et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol. Psychiatry51(9), 723–732 (2002).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Ito K, Sato K et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry26(2), 383–386 (2002).
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry7(10), 1115–1119 (2002).
   PubMed Web of Science ®Google Scholar
• Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J. Clin. Psychopharmacol.23(6), 563–567 (2003).
   PubMed Web of Science ®Google Scholar
• Joyce PR, Mulder RT, Luty SE et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptyline. Int. J. Neuropsychopharmacol.6(4), 339–346 (2003).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Mischoulon D, Smoller JW et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry54(9), 879–883 (2003).
   PubMed Web of Science ®Google Scholar
• Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl.)174(4), 525–529 (2004).
   PubMed Web of Science ®Google Scholar
• Lee MS, Lee HY, Lee HJ, Ryu SH. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr. Genet.14(2), 111–115 (2004).
   PubMed Web of Science ®Google Scholar
• Murphy GM. Pharmacogeneties in geriatric major depression. J. Affect. Disord.78, S35–S36 (2004).
   Google Scholar
• Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry9(9), 879–889 (2004).
   PubMed Web of Science ®Google Scholar
• Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet.129B(1), 36–40 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Takahashi H, Higuchi H et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am. J. Psychiatry161(9), 1575–1580 (2004).
   PubMed Web of Science ®Google Scholar
• Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol. Psychiatry58(5), 374–381 (2005).
   PubMed Web of Science ®Google Scholar
• Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J.6(1), 27–33 (2006).
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Wakeno M et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology53(4), 186–195 (2006).
   PubMed Web of Science ®Google Scholar
• Kim H, Lim SW, Kim S et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA296(13), 1609–1618 (2006).
   PubMed Web of Science ®Google Scholar
• Ng CH, Easteal S, Tan S, Schweitzer I, Ho BK, Aziz S. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog. Neuropsychopharmacol. Biol. Psychiatry30(5), 953–957 (2006).
   PubMed Web of Science ®Google Scholar
• Popp J, Leucht S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy – a pilot study. Pharmacogenomics7(2), 159–166 (2006).
   PubMed Web of Science ®Google Scholar
• Hu XZ, Rush AJ, Charney D et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry64(7), 783–792 (2007).
   PubMed Web of Science ®Google Scholar
• Kang RH, Wong ML, Choi MJ, Paik JW, Lee MS. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry31(6), 1317–1321 (2007).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J.7(1), 48–55 (2007).
   PubMed Web of Science ®Google Scholar
• Kraft JB, Peters EJ, Slager SL et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol. Psychiatry61(6), 734–742 (2007).
   PubMed Web of Science ®Google Scholar
• Bozina N, Peles AM, Sagud M, Bilusic H, Jakovljevic M. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J. Biol. Psychiatry9(3), 190–197 (2008).
   PubMed Web of Science ®Google Scholar
• Dogan O, Yuksel N, Ergun MA et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet. Test.12(2), 225–231 (2008).
   PubMedGoogle Scholar
• Mrazek DA, Rush AJ, Biernacka JM et al. SLC6A4 variation and citalopram response. Am. J. Med. Genet. B Neuropsychiatr. Genet.150B(3), 341–351 (2008).
   Web of Science ®Google Scholar
• Huezo-Diaz P, Uher R, Smith R et al. Moderation of antidepressant response by the serotonin transporter gene. Br. J. Psychiatry195(1), 30–38 (2009).
   PubMed Web of Science ®Google Scholar
• Maron E, Tammiste A, Kallassalu K et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur. Neuropsychopharmacol.19(6), 451–456 (2009).
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Ooteman W, Booij J et al. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet. Genomics19(1), 67–76 (2009).
   PubMed Web of Science ®Google Scholar
• Wilkie MJ, Smith G, Day RK et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics. J.9(1), 61–70 (2009).
   PubMed Web of Science ®Google Scholar
• Baffa A, Hohoff C, Baune BT et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology62(2), 121–131 (2010).
   PubMed Web of Science ®Google Scholar
• Lee SH, Choi TK, Lee E et al. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology62(3), 198–206 (2010).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol. Psychiatry67(11), 1110–1113 (2010).
   PubMed Web of Science ®Google Scholar
• Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican–Americans. Mol. Psychiatry14(12), 1105–1118 (2009).
   PubMed Web of Science ®Google Scholar
• Uher R, Huezo-Diaz P, Perroud N et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J.9(4), 225–233 (2009).
   PubMed Web of Science ®Google Scholar
• Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem.66(6), 2621–2624 (1996).
   PubMed Web of Science ®Google Scholar
• Hu XZ, Lipsky RH, Zhu G et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive–compulsive disorder. Am. J. Hum. Genet.78(5), 815–826 (2006).
   PubMed Web of Science ®Google Scholar
• Serretti A, Kato M, De RD, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry12(3), 247–257 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol. Psychiatry68(6), 536–43 (2010).
   PubMed Web of Science ®Google Scholar
• Delbruck SJ, Wendel B, Grunewald I et al. A novel allelic variant of the human serotonin transporter gene regulatory polymorphism. Cytogenet. Cell Genet.79(3–4), 214–220 (1997).
   PubMedGoogle Scholar
• Gelernter J, Kranzler H, Cubells JF. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African– and European–American and Japanese populations and in alcohol-dependent subjects. Hum. Genet.101(2), 243–246 (1997).
   PubMed Web of Science ®Google Scholar
• Keers R, Aitchison KJ. Gender differences in antidepressant drug response. Int. Rev. Psychiatry22(5), 1–16 (2010).
   PubMed Web of Science ®Google Scholar
• Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br. J. Pharmacol.151(6), 737–748 (2007).
   PubMed Web of Science ®Google Scholar
• Schomig E, Fischer P, Schonfeld CL, Trendelenburg U. The extent of neuronal re-uptake of 3H-noradrenaline in isolated vasa deferentia and atria of the rat. Naunyn Schmiedebergs Arch. Pharmacol.340(5), 502–508 (1989).
   PubMed Web of Science ®Google Scholar
• Leonard BE. The role of noradrenaline in depression: a review. J. Psychopharmacol.11(4 Suppl.), S39-S47 (1997).
   Google Scholar
• Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry46(9), 1219–1233 (1999).
   PubMed Web of Science ®Google Scholar
• Porzgen P, Bonisch H, Hammermann R, Bruss M. The human noradrenaline transporter gene contains multiple polyadenylation sites and two alternatively spliced C-terminal exons. Biochim. Biophys. Acta1398(3), 365–370 (1998).
   PubMedGoogle Scholar
• Kim CH, Kim HS, Cubells JF, Kim KS. A previously undescribed intron and extensive 5’ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J. Biol. Chem.274(10), 6507–6518 (1999).
   PubMed Web of Science ®Google Scholar
• Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci.15(7), 220–226 (1994).
   PubMed Web of Science ®Google Scholar
• Drevets WC, Thase ME, Moses-Kolko EL et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol.34(7), 865–877 (2007).
   PubMed Web of Science ®Google Scholar
• Drevets WC. Neuroimaging studies of mood disorders. Biol. Psychiatry48(8), 813–829 (2000).
   PubMed Web of Science ®Google Scholar
• Leysen JE. 5-HT2 receptors. Curr. Drug Targets. CNS Neurol. Disord.3(1), 11–26 (2004).
   PubMedGoogle Scholar
• Papolos DF, Yu YM, Rosenbaum E, Lachman HM. Modulation of learned helplessness by 5-hydroxytryptamine2A receptor antisense oligodeoxynucleotides. Psychiatry Res.63(2–3), 197–203 (1996).
   PubMed Web of Science ®Google Scholar
• Minov C, Baghai TC, Schule C et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci. Lett.303(2), 119–122 (2001).
   PubMed Web of Science ®Google Scholar
• Cusin C, Serretti A, Zanardi R et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int. J. Neuropsychopharmacol.5(1), 27–35 (2002).
   PubMed Web of Science ®Google Scholar
• Sato K, Yoshida K, Takahashi H et al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology46(3), 136–140 (2002).
   PubMed Web of Science ®Google Scholar
• Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res.1118(1), 176–182 (2006).
   PubMed Web of Science ®Google Scholar
• McMahon FJ, Buervenich S, Charney D et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet.78(5), 804–814 (2006).
   PubMed Web of Science ®Google Scholar
• Kang RH, Choi MJ, Paik JW, Hahn SW, Lee MS. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int. J. Psychiatry Med.37, 315–329 (2007).
   PubMed Web of Science ®Google Scholar
• Horstmann S, Lucae S, Menke A et al. Association of GRIK4 and HTR2A genes with antidepressant treatment in the MARS cohort of depressed inpatients. Eur. Neuropsychopharmacol.18, S214–S215 (2008).
   Google Scholar
• Illi A, Setala-Soikkeli E, Viikki M et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport20(12), 1125–1128 (2009).
   PubMed Web of Science ®Google Scholar
• Kishi T, Yoshimura R, Kitajima T et al.HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular. Med.12(3), 237–242 (2009).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol. Psychiatry65(9), 785–791 (2009).
   PubMed Web of Science ®Google Scholar
• Lucae S, Ising M, Horstmann S et al.HTR2A gene variation is involved in antidepressant treatment response. Eur. Neuropsychopharmacol.20(1), 65–68 (2010).
   PubMed Web of Science ®Google Scholar
• Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int. J. Neuropsychopharmacol.7(4), 501–506 (2004).
   PubMed Web of Science ®Google Scholar
• Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int. J. Neuropsychopharmacol.7(4), 453–460 (2004).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Sawamura K, Someya T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J.4(4), 283–286 (2004).
   PubMed Web of Science ®Google Scholar
• Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J. Psychopharmacol.19(2), 166–172 (2005).
   PubMed Web of Science ®Google Scholar
• Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology31(8), 1745–1749 (2006).
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur. Neuropsychopharmacol.16(7), 498–503 (2006).
   PubMed Web of Science ®Google Scholar
• Levin GM, Bowles TM, Ehret MJ et al. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol. Diagn. Ther.11(3), 155–160 (2007).
   PubMed Web of Science ®Google Scholar
• Baune BT, Hohoff C, Roehrs T, Deckert J, Arolt V, Domschke K. Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression? Neurosci. Lett.436(2), 111–115 (2008).
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Wakeno M et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet.150B(1), 115–123 (2009).
   PubMed Web of Science ®Google Scholar
• Parsons MJ, D’Souza UM, Arranz MJ, Kerwin RW, Makoff AJ. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry56(6), 406–410 (2004).
   PubMed Web of Science ®Google Scholar
• Choi MJ, Kang RH, Ham BJ, Jeong HY, Lee MS. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology52(3), 155–162 (2005).
   PubMed Web of Science ®Google Scholar
• Horstmann S, Lucae S, Menke A et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology35(3), 727–740 (2010).
   PubMed Web of Science ®Google Scholar
• Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip–flop phenomenon. Am. J. Hum. Genet.80(3), 531–538 (2007).
   PubMed Web of Science ®Google Scholar
• Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry6(5), 586–592 (2001).
   PubMed Web of Science ®Google Scholar
• Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur. Neuropsychopharmacol.11(5), 375–380 (2001).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Naito S, Takahashi H et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry26(7–8), 1279–1283 (2002).
   PubMed Web of Science ®Google Scholar
• Ham BJ, Lee MS, Lee HJ et al. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr. Genet.15(4), 299–301 (2005).
   PubMed Web of Science ®Google Scholar
• Ham BJ, Lee BC, Paik JW et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog. Neuropsychopharmacol. Biol. Psychiatry31(1), 104–107 (2007).
   PubMed Web of Science ®Google Scholar
• Kato M, Wakeno M, Okugawa G et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology56(4), 167–171 (2007).
   PubMed Web of Science ®Google Scholar
• Viikki M, Kampman O, Illi A et al. TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci. Lett.468(1), 80–84 (2010).
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Brockmoller J, Roots I, Kirchheiner J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet. Genomics18(6), 495–506 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Hong CJ, Liou YJ et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog. Neuropsychopharmacol. Biol. Psychiatry33(4), 637–641 (2009).
   PubMed Web of Science ®Google Scholar
• Szegedi A, Rujescu D, Tadic A et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J.5(1), 49–53 (2005).
   PubMed Web of Science ®Google Scholar
• Arias B, Serretti A, Lorenzi C, Gasto C, Catalan R, Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J. Affect. Disord.90(2–3), 251–256 (2006).
   PubMed Web of Science ®Google Scholar
• Baune BT, Hohoff C, Berger K et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology33(4), 924–932 (2008).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Higuchi H, Takahashi H et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum. Psychopharmacol.23(2), 121–128 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, Chen TJ. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J. Affect. Disord.113(1–2), 183–187 (2009).
   PubMed Web of Science ®Google Scholar
• Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl.)203(1), 155–160 (2009).
   PubMed Web of Science ®Google Scholar
• Benedetti F, Dallaspezia S, Colombo C, Lorenzi C, Pirovano A, Smeraldi E. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur. Psychiatry DOI: 10.1016/j.eurpsy.2009.12.007 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Muller DJ, Schulze TG, Macciardi F et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry35(4), 157–158 (2002).
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology30(9), 1719–1723 (2005).
   PubMed Web of Science ®Google Scholar
• Tadic A, Muller MJ, Rujescu D et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am. J. Med. Genet. B Neuropsychiatr. Genet.144B(3), 325–331 (2007).
   PubMed Web of Science ®Google Scholar
• Domschke K, Hohoff C, Mortensen LS et al. Monoamine oxidase A variant influences antidepressant treatment response in female patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry32(1), 224–228 (2008).
   PubMed Web of Science ®Google Scholar
• Tzeng DS, Chien CC, Lung FW, Yang CY. MAOA gene polymorphisms and response to mirtazapine in major depression. Hum. Psychopharmacol.24(4), 293–300 (2009).
   PubMed Web of Science ®Google Scholar
• Tadic A, Rujescu D, Muller MJ et al. A monoamine oxidase B gene variant and short-term antidepressant treatment response. Prog. Neuropsychopharmacol Biol. Psychiatry31(7), 1370–1377 (2007).
   PubMed Web of Science ®Google Scholar
• Nielsen DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M. Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Arch. Gen. Psychiatry51(1), 34–38 (1994).
   PubMed Web of Science ®Google Scholar
• Davidson JR, McLeod MN, Turnbull CD, White HL, Feuer EJ. Catechol-O-methyltransferase activity and classification of depression. Biol. Psychiatry14(6), 937–942 (1979).
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, Kolsky AR et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J. Clin. Psychopharmacol.19(4), 329–335 (1999).
   PubMed Web of Science ®Google Scholar
• Dempster EL, Mill J, Craig IW, Collier DA. The quantification of COMT mRNA in post mortem cerebellum tissue: diagnosis, genotype, methylation and expression. BMC Med. Genet.7, 10 (2006).
   PubMed Web of Science ®Google Scholar
• Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics6(3), 243–250 (1996).
   PubMedGoogle Scholar
• Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu.Rev.Neurosci.22, 197–217 (1999).
   PubMed Web of Science ®Google Scholar
• Meyer JH, Ginovart N, Boovariwala A et al. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry63(11), 1209–1216 (2006).
   PubMed Web of Science ®Google Scholar
• Henkel V, Mergl R, Allgaier AK, Kohnen R, Moller HJ, Hegerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res.141(1), 89–101 (2006).
   PubMed Web of Science ®Google Scholar
• Deckert J, Catalano M, Syagailo YV et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum. Mol. Genet.8(4), 621–624 (1999).
   PubMed Web of Science ®Google Scholar
• Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE. Monoamine oxidase A and catechol-O-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J. Clin. Psychopharmacol.29(4), 372–377 (2009).
   PubMed Web of Science ®Google Scholar
• Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci.31(9), 464–468 (2008).
   PubMed Web of Science ®Google Scholar
• Pariante CM. The glucocorticoid receptor: part of the solution or part of the problem? J. Psychopharmacol.20(4 Suppl.), 79–84 (2006).
   PubMedGoogle Scholar
• Binder EB, Salyakina D, Lichtner P et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet.36(12), 1319–1325 (2004).
   PubMed Web of Science ®Google Scholar
• Lekman M, Laje G, Charney D et al. The FKBP5-gene in depression and treatment response – an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol. Psychiatry63(12), 1103–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Lorch R, Lebedeva E et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics9(7), 841–846 (2008).
   PubMed Web of Science ®Google Scholar
• Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect. Disord.104(1–3), 83–90 (2007).
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Hong CJ, Chen TJ, Yu YW. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am. J. Med. Genet. B Neuropsychiatr. Genet.144B(8), 1097–1098 (2007).
   PubMed Web of Science ®Google Scholar
• Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM Jr. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am. J. Med. Genet. B Neuropsychiatr. Genet.153B(2), 554–560 (2010).
   PubMed Web of Science ®Google Scholar
• Licinio J, O’Kirwan F, Irizarry K et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican–Americans. Mol. Psychiatry9(12), 1075–1082 (2004).
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhu F, Wang G et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci. Lett.414(2), 155–158 (2007).
   PubMed Web of Science ®Google Scholar
• Brouwer JP, Appelhof BC, van Rossum EF et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology31(10), 1154–1163 (2006).
   PubMed Web of Science ®Google Scholar
• van Rossum EF, Binder EB, Majer M et al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol. Psychiatry59(8), 681–688 (2006).
   PubMed Web of Science ®Google Scholar
• Binder EB. The co-chaperone FKBP5, stress hormone system regulation and antidepressant drug response. Biol. Psychiatry61(8), 106S–106S (2007).
   Google Scholar
• Stein DJ, Daniels WM, Savitz J, Harvey BH. Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology. CNS Spectr.13(11), 945–949 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am. J. Med. Genet. B Neuropsychiatr. Genet.123B(1), 19–22 (2003).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Higuchi H, Kamata M et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J. Psychopharmacol.21(6), 650–656 (2007).
   PubMed Web of Science ®Google Scholar
• Gratacos M, Soria V, Urretavizcaya M et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J.8(2), 101–112 (2008).
   PubMed Web of Science ®Google Scholar
• Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch. Gen. Psychiatry66(5), 488–497 (2009).
   PubMed Web of Science ®Google Scholar
• Chi MH, Chang HH, Lee SY et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J. Affect. Disord.126(3), 430–435 (2010).
   PubMed Web of Science ®Google Scholar
• Domschke K, Lawford B, Laje G et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int. J. Neuropsychopharmacol.13(1), 93–101 (2010).
   PubMed Web of Science ®Google Scholar
• Zou YF, Wang Y, Liu P et al. Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. Hum. Psychopharmacol.25(2), 145–152 (2010).
   PubMed Web of Science ®Google Scholar
• Egan MF, Kojima M, Callicott JH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell112(2), 257–269 (2003).
   PubMed Web of Science ®Google Scholar
• Perroud N, Aitchison KJ, Uher R et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology34(12), 2517–2528 (2009).
   PubMed Web of Science ®Google Scholar
• Garriock HA, Kraft JB, Shyn SI et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry67(2), 133–138 (2010).
   PubMed Web of Science ®Google Scholar
• Ising M, Lucae S, Binder EB et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry66(9), 966–975 (2009).
   PubMed Web of Science ®Google Scholar
• Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry167(5), 555–564 (2010).
   PubMed Web of Science ®Google Scholar
• Ishii M, Maeda N. Oversulfated chondroitin sulfate plays critical roles in the neuronal migration in the cerebral cortex. J. Biol. Chem.283(47), 32610–32620 (2008).
   PubMed Web of Science ®Google Scholar
• Jetten AM, Kurebayashi S, Ueda E. The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog. Nucleic Acid Res. Mol. Biol.69, 205–247 (2001).
   PubMed Web of Science ®Google Scholar
• Uher R. The implications of gene–environment interactions in depression: will cause inform cure? Mol. Psychiatry13(12), 1070–1078 (2008).
   PubMed Web of Science ®Google Scholar
• Keers R, Uher R, Gupta B et al. Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. J. Affect. Disord.127(1–3), 337–342 (2010).
   PubMed Web of Science ®Google Scholar
• Keers R, Uher R, Huezo-Diaz P et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J. DOI: 10.1038/tpj.2010.14 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Reno RM, Halaris AE. The relationship between life stress and depression in an endogenous sample. Compr. Psychiatry31(1), 25–33 (1990).
   PubMed Web of Science ®Google Scholar
• Andrew B, Hawton K, Fagg J, Westbrook D. Do psychosocial factors influence outcome in severely depressed female psychiatric in-patients? Br. J. Psychiatry163, 747–754 (1993).
   PubMed Web of Science ®Google Scholar
• Mazure CM, Bruce ML, Maciejewski PK, Jacobs SC. Adverse life events and cognitive-personality characteristics in the prediction of major depression and antidepressant response. Am. J. Psychiatry157(6), 896–903 (2000).
   PubMed Web of Science ®Google Scholar
• Mandelli L, Serretti A, Marino E, Pirovano A, Calati R, Colombo C. Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. Int. J. Neuropsychopharmacol.10(4), 437–447 (2007).
   PubMed Web of Science ®Google Scholar
• Drury SS, Theall KP, Smyke AT et al. Modification of depression by COMT val158met polymorphism in children exposed to early severe psychosocial deprivation. Child Abuse Negl.34(6), 387–395 (2010).
   PubMed Web of Science ®Google Scholar
• Hosang GM, Uher R, Keers R et al. Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder. J. Affect. Disord.125(1–3), 345–349 (2010).
   PubMed Web of Science ®Google Scholar
• Kim JM, Stewart R, Kim SW et al. Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders. Biol. Psychiatry62(5), 423–428 (2007).
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Bradley B, Mercer KB et al. Polymorphisms in CRHR1 and the serotonin transporter loci: gene × gene × environment interactions on depressive symptoms. Am. J. Med. Genet. B Neuropsychiatr. Genet153B(3), 812–824 (2010).
   PubMed Web of Science ®Google Scholar
• Bradley RG, Binder EB, Epstein MP et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry65(2), 190–200 (2008).
   PubMed Web of Science ®Google Scholar
• Beach SR, Brody GH, Gunter TD, Packer H, Wernett P, Philibert RA. Child maltreatment moderates the association of MAOA with symptoms of depression and antisocial personality disorder. J. Fam. Psychol.24(1), 12–20 (2010).
   PubMed Web of Science ®Google Scholar
• Kim-Cohen J, Caspi A, Taylor A et al. MAOA, maltreatment, and gene–environment interaction predicting children’s mental health: new evidence and a meta-analysis. Mol. Psychiatry11(10), 903–913 (2006).
   PubMed Web of Science ®Google Scholar
• Binder EB, Bradley RG, Liu W et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA299(11), 1291–1305 (2008).
   PubMed Web of Science ®Google Scholar
• Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology35(8), 1674–1683 (2010).
   PubMed Web of Science ®Google Scholar
• Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry167(5), 509–527 (2010).
   PubMed Web of Science ®Google Scholar
• Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science301(5631), 386–389 (2003).
   PubMed Web of Science ®Google Scholar
• Mandelli L, Marino E, Pirovano A et al. Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur. Neuropsychopharmacol.19(1), 64–67 (2009).
   PubMed Web of Science ®Google Scholar
• Bukh JD, Bock C, Vinberg M, Werge T, Gether U, Kessing LV. No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment. Eur. Neuropsychopharmacol.20(5), 327–335 (2010).
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Clinically relevant effect sizes in depression. Eur. Neuropsychopharmacol.4(3), 283–284 (1994).
   Google Scholar
• Mulder RT, Joyce PR, Frampton C. Relationships among measures of treatment outcome in depressed patients. J. Affect. Disord.76(1–3), 127–135 (2003).
   PubMed Web of Science ®Google Scholar
• Streiner DL. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can. J. Psychiatry47(3), 262–266 (2002).
   PubMed Web of Science ®Google Scholar
• Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm. Stat.7(2), 93–106 (2008).
   PubMed Web of Science ®Google Scholar
• Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Arch. Gen. Psychiatry41(8), 782–786 (1984).
   PubMed Web of Science ®Google Scholar
• Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Arch. Gen. Psychiatry44(3), 259–264 (1987).
   PubMed Web of Science ®Google Scholar
• Rietschel M, Kennedy JL, Macciardi F, Meltzer HY. Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. Schizophr. Res.37(2), 191–196 (1999).
   PubMedGoogle Scholar
• Uher R, Muthen B, Souery D et al. Trajectories of change in depression severity during treatment with antidepressants. Psychol. Med.40(8), 1367–1377 (2010).
   PubMed Web of Science ®Google Scholar
• Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J.8(2), 90–100 (2008).
   PubMed Web of Science ®Google Scholar
• Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr.13(8), 663–681 (2008).
   PubMed Web of Science ®Google Scholar
• Hunter AM, Muthen BO, Cook IA, Leuchter AF. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. J. Psychiatr. Res.44(2), 90–98 (2010).
   PubMed Web of Science ®Google Scholar
• Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nat. Rev. Neurosci.9(8), 638–646 (2008).
   PubMed Web of Science ®Google Scholar